AAD: off-label and future rosacea treatments

Written by on April 2, 2009 in in the news with 0 Comments

As promised in my 67th AAD Meeting SFO, rosacea highlights news item, here are some updates from the conference proceedings and handouts. In this update we’ll look at a couple of slides from Dr. Thiboutot.

I found it very encouraging to see such an up to date list of possibilities being discussed at an AAD forum.

Of course only being able to read the slides doesn’t compare to actually attending, but nonetheless it is still an encouraging sign that this level of forward looking is permeating the ranks of dermatologists.

FRM F013, Problem Cases of Rosacea, Diane M. Thiboutot, M.D., Professor of Dermatology, The Pennsylvania State University, College of Medicine, Hershey, PA.

Dr. Thiboutot notes that she is a clinical trials investigator and consultant to Galderma and Intendis. Also investigator or consultant to Allergan, Arcutis, Obagi and Stiefel.

Slide 23: Agents reported (off-label) in rosacea

Slide 25: Possible future treatments

Related Articles

Read more about: in the news

About the Author

About the Author: David Pascoe started the Rosacea Support Group in October 1998. .

Follow Rosacea Support

Subscribe via RSS Feed Connect on Pinterest Connect on Google Plus

Leave your comment here


Subscribe to Rosacea News

Enter your email address to receive the latest news about rosacea in your inbox.